Tazidime and Bradycardia - a phase IV clinical study of FDA data

Summary:

Bradycardia is reported as a side effect among people who take Tazidime (ceftazidime), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Vancomycin, and have Atrial fibrillation/flutter.

The phase IV clinical study analyzes which people have Bradycardia when taking Tazidime. It is created by eHealthMe based on reports of 10,389 people who have side effects when taking Tazidime from the FDA, and is updated regularly.

What is Tazidime?

Tazidime has active ingredients of ceftazidime. eHealthMe is studying from 10,409 Tazidime users. Check the latest studies of Tazidime.

What is Bradycardia?

Bradycardia (abnormally slow heart action) is found to be associated with 1,924 drugs and 3,119 conditions by eHealthMe. Check the latest studies of Bradycardia.

On Jul, 23, 2026

10,389 people reported to have side effects when taking Tazidime.
Among them, 98 people (0.94%) have Bradycardia.

Among these 98 people:

How long have people been on Tazidime when they have Bradycardia? *

What is the gender of people who have Bradycardia when taking Tazidime? *

female: 40 %
male: 60 %

What is the age of people who have Bradycardia when taking Tazidime? *

What are other drugs people take besides Tazidime? *

What are other side effects people have besides Bradycardia? *

Hypotension (abnormally low blood pressure): 19 people, 19.39%
Cardiac Arrest: 18 people, 18.37%
Haemoglobin Decreased: 11 people, 11.22%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 11 people, 11.22%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 10 people, 10.20%
Fever: 10 people, 10.20%
Pleural Effusion (water on the lungs): 9 people, 9.18%
Thrombocytopenia (decrease of platelets in blood): 9 people, 9.18%
Electrocardiogram Qt Prolonged: 9 people, 9.18%
Arrhythmias (irregular heartbeat): 9 people, 9.18%

What are the existing conditions these people have? *

Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 9 people, 9.18%
Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 6 people, 6.12%
Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 6 people, 6.12%
Ventricular Extrasystoles (premature cardiac contraction): 5 people, 5.10%
Asthma: 5 people, 5.10%
Breast Cancer: 5 people, 5.10%
Arrhythmias (irregular heartbeat): 5 people, 5.10%
Respiratory Acidosis (respiratory failure or ventilatory failure, causes the ph of blood and other bodily fluids to decrease): 4 people, 4.08%
Pneumonia: 3 people, 3.06%
Pneumonia Pseudomonal (pseudomonas pneumonia is an infection caused by the microbe known as pseudomonas aeruginosa): 3 people, 3.06%

* Approximation only. Some reports may have incomplete information.

Do you take Tazidime and have Bradycardia?

- Check whether Bradycardia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tazidime:

Tazidime (10,409 reports)

Bradycardia treatments and more:

Bradycardia (61,180 reports)

Browse all side effects of Tazidime:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Bradycardia:

Bradycardia (1,924 drugs)

Browse all the conditions that are associated with Bradycardia:

Bradycardia (3,119 conditions)

Related publications that referenced our studies

Chen F, Zhan Z, "Severe drug-induced immune haemolytic anaemia due to ceftazidime", Blood Transfusion, 2014 Jan .
Schlumbrecht MP, Hehr K, "Cisplatin-induced bradycardia and the importance of the QT interval", Journal of Oncology Pharmacy Practice, 2015 Jan .
Oflaz MB, Kucukdurmaz Z, Guven AS, Karapinar H, Kaya A, Sancakdar E, Deveci K, Gul I, Erdem A, Cevit O, Icagasioglu FD, "Bradycardia seen in children with Crimean-Congo hemorrhagic fever", Vector-Borne and Zoonotic Diseases, 2013 Nov .
Chen F, Zhan Z, "Severe drug-induced immune haemolytic anaemia due to ceftazidime", Blood Transfusion, 2014 Jan .
Schlumbrecht MP, Hehr K, "Cisplatin-induced bradycardia and the importance of the QT interval", Journal of Oncology Pharmacy Practice, 2015 Jan .
Oflaz MB, Kucukdurmaz Z, Guven AS, Karapinar H, Kaya A, Sancakdar E, Deveci K, Gul I, Erdem A, Cevit O, Icagasioglu FD, "Bradycardia seen in children with Crimean-Congo hemorrhagic fever", Vector-Borne and Zoonotic Diseases, 2013 Nov .

How the study uses the data?

The study uses data from the FDA. It is based on ceftazidime (the active ingredients of Tazidime) and Tazidime (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.